All animal experiments were conducted in accordance with standard institute animal care and use committee protocols. C57BL/6 mice obtained from Jackson Laboratory were injected through the tail vein with C1498FFDsR (5 × 106) to achieve systemic engraftment to the degree reported in the literature [8 (link),11 (link),12 (link)]. Seven days following AML injection, they were initiated on treatment with vehicle, DMXAA, anti-PD-1 ab (Bio Xcell), or combination of DMXAA and anti-PD-1 ab. Treatment with either DMXAA at 20mg/kg or vehicle was administered intraperitoneally every four days for a total of six weeks. anti-PD-1 ab was administered intraperitoneally at 10mg/kg on days 7, 10, 13, and 16.
Anti pd 1 ab
Manufactured by BioXCell
Anti-PD-1 Ab is a monoclonal antibody that binds to the programmed cell death-1 (PD-1) receptor. PD-1 is an immune checkpoint protein that regulates T-cell activation and function. The Anti-PD-1 Ab can be used in research to study the role of the PD-1 pathway in immune response and its potential therapeutic applications.
Automatically generated - may contain errors
6 protocols using anti pd 1 ab
1
AML Treatment with DMXAA and Anti-PD-1 Antibody
2
In vivo Pancreatic Cancer Treatments
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
In vivo treatments were completed as previously described.21 (link) Briefly, KPC-Brca2 mice (5 weeks of age) were treated with isotype control or anti-CD200 Ab at a dose of 200 µg/mouse, three times each week (Monday, Wednesday, and Friday). Following 2 weeks of treatment, animals were euthanized via CO2 asphyxiation, followed by cardiac puncture. Splenocytes and tumor tissue were collected for further analysis. Pathology was assessed in H&E stained slides to determine the differentiation state of tissue as pancreatic intraepithelial neoplasia (PanIN)−1, PanIN-2, PanIN-3, or PDAC. For studies using MT5 tumor cells, 1×106 cells were injected subcutaneously in the flank of C57BL/6 mice and injected intraperitoneally three times each week with 200 µg/mouse of isotype, anti-CD200 and/or anti-PD-1 Ab (BioXCell) treatment starting once tumors reached 50–100 mm3 volume.
3
Curcumin Enhances Anti-PD-1/PD-L1 Therapy
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
For combination with PD‐1/PD‐L1 blockade, mice received po administration with 5 mg/kg of curcumin diluted in water every day starting on day 3 after implantation with MC38 until killed (day 20‐25). Control mice received water. Anti‐PD‐1 Ab (BioXcell, clone: RMP1‐14) and anti‐PD‐L1 Ab (BioXcell, clone: 10F.9G2) were given ip on days 7, 10, and 13 at a dose of 200 µg/100 µL/mouse. Rat IgG2a (BioXcell, clone: 2A3) and rat IgG2b (BioXcell, clone: LTF‐2) were injected ip in the control group and the curcumin single treatment group on days 7, 10, and 13 at a dose of 200 µg/100 µL/mouse.
4
Anti-PD-1 and ATRA in Tumor Growth
5
Adoptive cell transfer and PD-1 blockade in tumor
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
For ACT, mice were intravenously (i.v.) treated 7 days post-tumor injection with 1 × 106in vitro-activated CD3+, CD3+CX3CR1+, CD3+CX3CR1− cells or TILs. For PD-1 blockade, anti-PD-1 Ab (#BE0146，Bio X Cell) or PBS were intraperitoneally (i.p.) administered every three days starting from 3 days after ACT at a dose of 200 μg/mouse.
6
Combination Immunotherapy for Tumor Treatment
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
PTX (Sigma-Aldrich), anti-B and T lymphocyte attenuator (BTLA) Ab (clone 6A6, Bio X cell), and anti-PD-1 Ab (clone RMP1-14, Bio X cell) were administered intraperitoneally. Dose determination was performed.10 14 (link) PTX was applied at 6 mg/kg and 100 µg of anti-BTLA or anti-PD-1 Ab was used in each dose. Mice were challenged with 5×105 tumor cells on day 0. For the PTX alone group, daily PTX was started on day 14. For the PTX and ICB group, PTX was used daily from day 14 and ICB (anti-BTLA Ab, anti-PD-1 Ab, or both) was applied twice a week from day 16. The immune profiles and tumor volumes of the tumor-bearing mice with or without treatment were analyzed on day 35. Splenocytes were prepared, as well as the supernatants and TACs of ascites, and tumor bioluminescence was detected.10 11 15 (link) The remaining animals were maintained until day 100 or death for survival analyses.
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!